Ibuprofen strategic options to be finalized in H1 FY27
Bankers appointed to evaluate strategic options for ibuprofen business; process expected to conclude in H1 FY27.
SOLARA / guidance tracker
Keep management guidance in view.
Solara Active Pharma Sciences · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
other
Debt-free target by FY29
Management aims to make Solara debt-free (including working capital) by FY29.
4-5 DMF filings per year starting FY27
Company plans to file 4-5 Drug Master Files annually, with first filed in April 2026.